Roivant Sciences Ltd (ROIV) concluded trading on Thursday at a closing price of $10.87, with 4.92 million shares of worth about $53.51 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 5.23% during that period and on February 06, 2025 the price saw a loss of about -0.91%. Currently the company’s common shares owned by public are about 733.33M shares, out of which, 448.17M shares are available for trading.
Stock saw a price change of -4.40% in past 5 days and over the past one month there was a price change of -5.56%. Year-to-date (YTD), ROIV shares are showing a performance of -8.11% which increased to 8.48% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $9.76 but also hit the highest price of $13.06 during that period. The average intraday trading volume for Roivant Sciences Ltd shares is 4.78 million. The stock is currently trading -1.43% below its 20-day simple moving average (SMA20), while that difference is down -6.58% for SMA50 and it goes to -4.56% lower than SMA200.
Roivant Sciences Ltd (NASDAQ: ROIV) currently have 733.33M outstanding shares and institutions hold larger chunk of about 67.72% of that.
The stock has a current market capitalization of $7.91B and its 3Y-monthly beta is at 1.26. PE ratio of stock for trailing 12 months is 1.92, while it has posted earnings per share of $5.66 in the same period. It has Quick Ratio of 10.43 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ROIV, volatility over the week remained 2.27% while standing at 2.65% over the month.
Analysts are in expectations that Roivant Sciences Ltd (ROIV) stock would likely to be making an EPS of -0.24 in the current quarter, while forecast for next quarter EPS is -0.22 and it is -0.99 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.33 which is -0.16 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.21 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -114.65% while it is estimated to decrease by -42.61% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wolfe Research on February 15, 2024 offering an Outperform rating for the stock and assigned a target price of $17 to it. Coverage by Piper Sandler stated Roivant Sciences Ltd (ROIV) stock as an Overweight in their note to investors on January 05, 2024, suggesting a price target of $20 for the stock. On December 12, 2023, Deutsche Bank Initiated their recommendations, while on October 17, 2023, Guggenheim Initiated their ratings for the stock with a price target of $17. Stock get a Neutral rating from BofA Securities on June 08, 2023.
